Hassan Mubark
Auckland Regnerative Clinic, New ZealandBiography
Dr Mubark is an experienced joint disease specialist with more than 30 years in medical practice. Specializing in Rheumatology from 2007, he became particularly interested in musculoskeletal and sports medicine as well as regenerative medicine. For many years he has worked in this field, starting with plasma (PRP) then moving to autologous fat-derived expanded mesenchymal stem cells therapy with growing interest over the past few years. Dr Mubark is an experienced joint disease specialist with more than 30 years in medical practice. Specializing in Rheumatology from 2007, he became particularly interested in musculoskeletal and sports medicine as well as regenerative medicine. For many years he has worked in this field, starting with plasma (PRP) then moving to autologous fat-derived expanded mesenchymal stem cells therapy with growing interest over the past few years. His main interest is interventional procedures that could lead to permanent life changes for patients. Dr Mubark’s treatment has seen several significant published successes in Orthopaedic journals, including treating the most challenging cases involving world champions to a number of published medical cases with success stories from knee, hip, shoulder, Achilles tendon and hands osteoarthritis and tendon tears. Despite being used overseas, stem cell therapy is classed as an ‘experimental or alternative’ procedure for musculoskeletal conditions in New Zealand and we follow and respect medico-ethical rules of the medical council and MedSafe, we perform our procedure using freedom of choice approach and informed consent. In New Zealand stem cell therapy is not funded by ACC and not offered within the public health system, but occasionally may be covered by private health insurance. Dr Mubark believes this procedure will eventually be available to all Kiwis, once sufficient research is published, and our medical fraternity have time to understand this complex new area of medicine. Stem cell therapy, when offered early to patients, has 70-80% success rate of controlling symptoms and improving quality of life. The idea is to slow or stop the progression of the degenerative joint disease and help tendon tear. Born in Iraq and trained at Baghdad University, Dr Mubark has had extensive hospital training in various specialties of general medicine, surgery, orthopaedics, and various other branches of medicine. Dr Mubark settled in New Zealand in 1995 and has worked ever since to bring the latest advances in medical science to his Kiwi patients with two main aims, to help those suffering from arthritis and injury, and to keep New Zealand at the forefront of world-leading medical science. Dr Mubark is working hard to bring the latest advances with two main aims - to help arthritis and injuries sufferers and to let New Zealand lead the world with good science. This determination has resulted in him receiving an award in 2023 for “Global Recognition for Innovative Stem Cell Therapy”.
Research Interest
Dr Mubark is an experienced joint disease specialist with more than 30 years in medical practice. Specializing in Rheumatology from 2007, he became particularly interested in musculoskeletal and sports medicine as well as regenerative medicine. For many years he has worked in this field, starting with plasma (PRP) then moving to autologous fat-derived expanded mesenchymal stem cells therapy with growing interest over the past few years. Dr Mubark is an experienced joint disease specialist with more than 30 years in medical practice. Specializing in Rheumatology from 2007, he became particularly interested in musculoskeletal and sports medicine as well as regenerative medicine. For many years he has worked in this field, starting with plasma (PRP) then moving to autologous fat-derived expanded mesenchymal stem cells therapy with growing interest over the past few years. His main interest is interventional procedures that could lead to permanent life changes for patients. Dr Mubark’s treatment has seen several significant published successes in Orthopaedic journals, including treating the most challenging cases involving world champions to a number of published medical cases with success stories from knee, hip, shoulder, Achilles tendon and hands osteoarthritis and tendon tears. Despite being used overseas, stem cell therapy is classed as an ‘experimental or alternative’ procedure for musculoskeletal conditions in New Zealand and we follow and respect medico-ethical rules of the medical council and MedSafe, we perform our procedure using freedom of choice approach and informed consent. In New Zealand stem cell therapy is not funded by ACC and not offered within the public health system, but occasionally may be covered by private health insurance. Dr Mubark believes this procedure will eventually be available to all Kiwis, once sufficient research is published, and our medical fraternity have time to understand this complex new area of medicine. Stem cell therapy, when offered early to patients, has 70-80% success rate of controlling symptoms and improving quality of life. The idea is to slow or stop the progression of the degenerative joint disease and help tendon tear. Born in Iraq and trained at Baghdad University, Dr Mubark has had extensive hospital training in various specialties of general medicine, surgery, orthopaedics, and various other branches of medicine. Dr Mubark settled in New Zealand in 1995 and has worked ever since to bring the latest advances in medical science to his Kiwi patients with two main aims, to help those suffering from arthritis and injury, and to keep New Zealand at the forefront of world-leading medical science. Dr Mubark is working hard to bring the latest advances with two main aims - to help arthritis and injuries sufferers and to let New Zealand lead the world with good science. This determination has resulted in him receiving an award in 2023 for “Global Recognition for Innovative Stem Cell Therapy”.